SOURCE: Bio-Quant, Inc.
BIO-QUANT AWARDED FULL AAALAC ACCREDITATION
SAN DIEGO, CA, October 27, 2008 --Bio-Quant Inc ("Bio-Quant") the largest biotech Contract Research Organization (CRO) in San Diego, announced today that it has received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) International. AAALAC is an internationally recognized, not-for-profit organization, which promotes the humane treatment of animals in science through voluntary accreditation and assessment programs.
As a result of an extensive on-site evaluation, AAALAC determined that Bio-Quant is committed to the highest level of animal care and research practices.
In addition, AAALAC noted the following in its official approval letter: that “The management and staff are commended for providing satisfactory facilities and programs for the care and use of laboratory animals. Especially noteworthy were the experienced leadership…of the Institutional Animal Care and Use committee (IACUC) chair and the Vivarium Manager and the comprehensive animal’s enrichment program.”
"The AAALAC accreditation comes as a result of our efforts to improve our service capabilities and operational infrastructure. With our recent infrastructure expansion and the addition of highly skilled personnel, Bio-Quant is committed to the highest reliability and commitment to our customers" said CEO Dr. Bassam Damaj. "This AAALAC site visit demonstrates our continual focus for the well being of our animals. Even though this accreditation is not a regulatory requirement, we felt it was important to show the level of quality and high standards Bio-Quant holds itself to. This accreditation demonstrates our commitment to the being the best possible CRO we can be, and we believe that this may bring us added business as a result."
About Bio-Quant, Inc.
Bio-Quant, Inc. is a profitable revenue-generating biotechnology pre-clinical contract research organization specializing in in vitro and in vivo pharmacology, PK and toxicology to support non-GLP pre-IND enabling studies in addition to vivarium housing services. The company specializes in pre-clinical work in the areas of Inflammation, Oncology, and Immunology, PK and toxicology services.
More information is available at
www.bio-quant.com.
Contact:
Bio-Quant, Inc.
Edward M. Cox, President +1-858-450-0048
ecox@bio-quant.com
or
Porter, LeVay & Rose, Inc. Michael J. Porter, President
Jeffrey Myhre, VP – Editorial 212-564-4700
back
